Chemical engineering

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genetics #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Metabolomics #Microbiome #Molecular medicine #Oncology #Patent Law #PCR #Pharmacogenomics #Pharmacokinetics / Pharmacodynamics #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Reigniting Pharmaceutical Innovation Through Holistic Drug Targeting

By Dr A Roy, Prof B Patwardhan and Dr R Chaguturu Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic. Secondly, none of the… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Animal models #Assay development optimisation & technology #Biomarkers #Business #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #Immunology #Lead discovery #Mass spectrometry / NMR #Metabolomics #Microbiology #Microbiome #Molecular medicine #Oncology #Pathology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Metabolomics – A Playbook for Functional Genomics

Metabolomics - A Playbook for Functional Genomics By Dr David Ferrick If we have learned anything from scientific research in the last 20 years, it is that finding cures to complex diseases is difficult. Despite the promise of the genomic revolution, disease progression and patient outcomes are still not easily… Read More

#Archive

High content screening
#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Molecular medicine #Pharmokinetics #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Latest Developments in High Content Screening Systems

By Dr John Comley High-content screening (HCS) is a well-established approach for the multiparametric analysis of cellular events. Since its first introduction more than a decade ago, high content imaging systems have continually evolved with many improvements enabled to meet user demands of greater flexibility and the growing requirements of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Automation / robotics #Business #Cell culture #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Genetics / genomes #Genetics / genomics #Genomics #High throughput screening #Lead discovery #Metabolomics #Microbiome #Organic chemistry #Protein chemistry / Proteomics #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics

With Synthetic Biology, Drug Discovery Is Going Virtual

With Synthetic Biology, Drug Discovery Is Going Virtual by Christopher Voigt Christopher Voigt is a professor of biological engineering at the Massachusetts Institute of Technology, where his lab focuses on synthetic biology. Two major areas of interest for him are developing a genetic programming language for cells and applying synthetic… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Metabolomics #Organic chemistry #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Microtissues For In Vitro Toxicity Assessment: Cost effective and in vivo relevant toxicology tools

Microtissues For In Vitro Toxicity Assessment: Cost effective and in vivo relevant toxicology tools By Dr Stephanie Ravenscroft, Dr Caroline Bauch, Dr Laura Hinton and Dr Paul Walker Conventional two-dimensional (2D) cell models (adherent cells grown on cell culture plates or cells in suspension) are limited in their abilities to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development optimisation & technology #Biochemistry #Biomarkers #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #High Content Screening #High throughput screening #Imaging #Lead discovery #Mass spectrometry / NMR #Oncology #Pathology #Pharmokinetics #Preclinical #Regulatory #RNA #Screening #Stem cells #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

The Coming Age Of Mass Spectrometry Imaging

The Coming Age Of Mass Spectrometry Imaging By Dr Peter J.H. Webborn and Dr Richard J.A. Goodwin Mapping complex drug distribution/retention in tissues, aligned with efficacy and safety biomarker localisation is now possible using label-free mass spectrometry imaging technologies. While there remain challenges to be overcome, these molecular imaging techniques… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Cell culture #Cell therapy #Cellular & Molecular biology #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Mass spectrometry / NMR #Molecular medicine #Oncology #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Synthetic Lethality and Anti Cancer Drug Discovery

Synthetic Lethality and Anti Cancer Drug Discovery By Jonathan D Moore Classically-activated oncogene targets have been a mainstay of cancer drug discovery for the past 15 years, but the druggable targets in this category have been largely mined out. Future efforts to drug the cancer genome must take synthetic lethal… Read More

#Archive

Stem cells
#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biobanking #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

The stem cell dilemma: Reprogramming in-house versus off-the-shelf

  by Dr John Comley The case for using more physiologically-relevant cells for modelling disease pathophysiology, for understanding a drug’s mechanism of action, in toxicology/safety testing and in phenotypic drug screening assays is now well accepted. Human induced pluripotent stem cells (iPSCs) are seen as a resource from which to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Chimeric Antigen Receptor T-cells (CAR-T): Looking beyond the hype

Chimeric Antigen Receptor T-cells (CAR-T): Looking beyond the hype By Christoph Oldenburg, Dr Markus Thunecke and Dr John Herrmann While Chimeric Antigen Receptor T-cells (CAR-T), have already demonstrated convincing efficacy in a specific setting, the jury is still out on whether they are a ‘game-changer’ for oncology as a whole… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Oncology #Pathology #PCR #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Phenotypic Drug Discovery: Striving towards high level biological relevance

Phenotypic Drug Discovery: Striving towards the highest level of biological relevance By Dr John Comley Phenotypic drug discovery (PDD) implies screening where the molecular mechanism of action is not assumed and does not require knowledge of the molecular target. As such phenotypic drug discovery is comparable to empirical screening, which… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Patent Law #PCR #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics

The California Institute for Regenerative Medicines Human iPSC Initiative

The California Institute for Regenerative Medicines Human iPSC Initiative By Dr Thomas J. Novak This article discusses large-scale generation of patient-derived induced pluripotent stem cells (iPSCs) to accelerate the understanding of disease biology and drug discovery. In 2012, the California Institute for Regenerative Medicine (CIRM) announced its Human iPSC Initiative,… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Animal models #Cell therapy #Cellular assays #Chemical engineering #Clinical specialities #Clinical trials #Drug development #Drug discovery #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Oncology #Pathology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Toxicology #Translational #Translational chemistry

The Increasing Impact of Precision Research Models on Drug Discovery and Development

The Increasing Impact of Precision Research Models on Drug Discovery and Development Dr Amar Thyagarajan Animal models are the standard by which we gain insight into the complex biological processes that underlie normal human physiology and disease states. Rodent models such as rats and mice have been used to understand… Read More

#Archive

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Business #Cell therapy #Chemical engineering #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Lead optimisation #Molecular medicine #Oncology #Patent Law #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #Therapeutics

mRNA Will Revolutionise the Biopharmaceutical Industry

mRNA Will Revolutionise the Biopharmaceutical Industry By Dr Ingmar Hoerr Messenger RNA (mRNA) - the naturally occurring molecule honed over thousands of years of evolution to translate accurately and efficiently the information encoded in a cell's DNA into the proteins essential for maintaining cell function and ensuring an organism’s survival,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Metabolomics #Oncology #PCR #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

New Developments in Single Cell Separation and Analysis Technologies

New Developments in Single Cell Separation and Analysis Technologies By Dr John Comley Drug Discovery Recent advances of single cell technologies are facilitating the opportunity to discern biological insights within individual cells and providing a means to reveal previously hidden relationships between individual cells within a population. Single cell technologies… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Automation / robotics #Business #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Enabling technologies #High Content Screening #Lead discovery #Medicinal chemistry #Regulatory #RNA #System biology #Systems biology #Translational #Translational chemistry

Managing Data Challenges In The New R&D Environment

Managing Data Challenges In The New R&D Environment By Dr Paul Denny-Gouldson The discovery and development of drugs is changing. The realm once dominated by ‘big pharma’ is becoming increasingly fragmented into more agile and flexible consortia. The dramatic change of focus on drug type from small molecule to large… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cell therapy #Cellular & Molecular biology #Chemical engineering #Clinical specialities #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Gene therapy #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #Oncology #Orphan drugs #Patent Law #Precision medicine #Regulatory #RNA #Screening #Sequencing #System biology #Systems biology #Toxicology

Therapeutic Drug Repurposing, Repositioning and Rescue Part III

Therapeutic Drug Repurposing, Repositioning and Rescue Part III: Market exclusivity using Intellectual Property and regulatory pathways By Dr Stephen Naylor, David M. Kauppi and Judge M. Schonfeld There is a growing consensus that Drug Repurposing, Repositioning and Rescue (DRPx) can impact the prescription drug industry for all concerned stakeholders. In… Read More

#Archive